Skip to content
StockMarketAgent
Direct answer
CI trades against a final fair-value range of $382.18-$742.98, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs. Fair value range: low $382, high $743, with mid-point at $561.
Stock analysis

CI CI fair value $382–$743

CI
By StockMarketAgent.AI team· supervised by
تم التحليل: 2026-05-12التحديث التالي: 2026-08-12Methodology v2.5Review: automatedArchetype: Mature compounder
View archive
السعر
$289.07
▲ +272.29 (+94.20%)
القيمة العادلة
$561
$382–$743
التصنيف
شراء قوي
confidence 83/100
إمكانية الصعود
+94.2%
upside to fair value
هامش الأمان
$477.16
MoS level · 15%
القيمة السوقية
$76.5B
P/E fwd 8.6
المصدر الإنجليزيAR
يتم عرض المصدر الإنجليزي أثناء الترجمة
لم تتم ترجمة هذا التقرير بعد. قم بالتحديث خلال بضع دقائق بمجرد أن تلحق قائمة انتظار الترجمة بالركب.

§1 الملخص التنفيذي

  • Composite fair value $561 with high case $743.
  • Implied upside of 94.2% to fair value.
  • Moat 9/10 · confidence 83/100 · Mature compounder.
  • Trades below fair value with a meaningful cushion to the midpoint.
Fair value
$561
Margin of safety
+48.5%
Confidence
83/100
Moat
9/10

Educational analysis only — not financial advice. Always do your own due diligence.

$289.07Price
Low $382.18
Mid $561.36
High $742.98

CI trades against a final fair-value range of $382.18-$742.98, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.

  • Evernorth scale and specialty pharmacy
    Evernorth scale and specialty pharmacy dominance
  • Vertical integration of PBM and
    Vertical integration of PBM and health benefits
  • Cycle upside
    Consolidation of specialty pharmacy and managed care services driving scale efficiencies.

§2 السيناريو الهبوطي

Sweeping legislative changes target PBM spread pricing and rebates, crippling Evernorth's profitability. At the same time, sudden medical cost inflation squeezes traditional insurance margins, limiting the cash available to service Cigna's massive debt load.

كيف يمكن أن تفشل هذه الأطروحة

PBM Spread Pricing Ban

· High

Federal legislation permanently bans spread pricing and mandates full rebate pass-throughs across all books of business.

FV impact
Moderate to Severe
Trigger
12-24 months

Medical Cost Spike

· Medium

Unanticipated structural increase in utilization rates compresses medical loss ratios beyond historical norms.

FV impact
Moderate
Trigger
6-12 months

De-leveraging Failure

· Low

Inability to service acquisition-related debt due to sustained margin compression, halting share repurchases.

FV impact
Severe
Trigger
24-36 months
إشارات الإنذار المبكر للمراقبة
المقياسالحاليحد التشغيل
Operating margins sustainably compressing toward the 3.0% industry median over 4 consecutive quarters.MonitorDeterioration versus the report thesis
Total corporate revenue actively dropping into negative YoY growth territory.MonitorDeterioration versus the report thesis
Unplanned suspension of the share repurchase program.MonitorDeterioration versus the report thesis
Medical care ratio (MCR) exceeding internal targets for two consecutive quarters.MonitorDeterioration versus the report thesis
Key enterprise client losses within the Evernorth segment.MonitorDeterioration versus the report thesis

§3 التاريخ المالي

بيان الدخل — آخر ستة فترات
البندT−0T−1T−2T−3T−4معدل النمو السنوي المركب
الفترة2021-12-312022-12-312023-12-312024-12-312025-12-31Trend
الإيرادات$174.27B$180.03B$195.19B$244.38B+8.8%
إجمالي الربح
الدخل التشغيلي
صافي الدخل$5.37B$6.70B$5.16B$3.43B-10.6%
EPS (مخفف)$21.30$17.39$12.12$22.18+1.0%
EBITDA
البحث والتطوير
المصاريف الإدارية والبيعية$13.01B$13.17B$14.82B$14.84B+3.3%

درجات الجودة

OCF / صافي الدخل
3.02×
>1 يشير إلى جودة عالية للأرباح
حد جودة المحاسبة
Fail
حد معدل حسب القطاع
ROIC
7.2%
العائد على رأس المال المستثمر
القسم 3

Numbers analysis

التدفق النقدي

Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.

تخصيص رأس المال

Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.

المشتركون الأفراد — من §4 فصاعداً11 قسماً إضافياً

اقرأ التحليل الكامل — 11 قسماً إضافياً.

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

تقرير كامل لكل سهم مغطى
أرشيف تصنيفات 24 شهراً
إيجازات قائمة المراقبة + تنبيهات تغيير التصنيف
تصدير PDF + DOCX بأي لغة
ابدأ تجربة مجانية
إلغاء في أي وقت.
FAQ

CI — frequently asked questions

  1. Based on our latest analysis, CI looks meaningfully undervalued. The current price is $289 versus a composite fair-value midpoint of $561 (range $382–$743), which implies roughly 94.2% upside to the midpoint.
Related coverage

Names readers of CI also follow

Same archetype: mature-compounder